# Nested Therapeutics

Source: https://onco.cc/companies/nested-therapeutics/  
OnCo record `nested-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nested Therapeutics hunts for hidden cancer-driving mutations and designs drugs to fit them. Its first drug, NST-628, sticks two signalling proteins (RAF and MEK) together to switch off a common cancer growth pathway.

## Summary

Nested Therapeutics is a Cambridge, Massachusetts precision oncology company founded by Versant Ventures. Its platform maps mutational clusters onto protein structures to reveal cryptic driver mutations and druggable pockets, combining genomics, computational biophysics and machine learning. The lead programme, NST-628, is a non-degrading, brain-penetrant pan-RAF/MEK molecular glue that outperformed single agents and vertical combinations in RAS/MAPK-driven preclinical models; it is in a phase 1 study (NCT06326411) in adults with MAPK pathway-mutated or -dependent advanced solid tumours. A mutation-selective p53 pathway programme targets a cryptic pocket in a transcriptional regulator and has a lead compound. Nested launched in October 2022 with a 90 million US dollar Series A led by Goldman Sachs Asset Management, bringing total funding to 125 million US dollars.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://nestedtx.com/

## Notes

- No SEC Form D filings were found under the company name. The seed funding (35 million US dollars implied by the 125 million total) is not itemised in the release. Founding year not sourced.

## Sources

- Official website: https://nestedtx.com/
- Launch and Series A press release (PDF): https://nestedtx.com/wp-content/uploads/2022/09/Nested-Launches-With-125-Million-Financing.pdf
- NST-628 phase 1 trial: https://clinicaltrials.gov/study/NCT06326411

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/), [TP53](https://onco.cc/targets/tp53/)
- companies: [Foresite Capital](https://onco.cc/companies/foresite-capital/), [Section 32 (S32)](https://onco.cc/companies/section-32/), [Versant Ventures](https://onco.cc/companies/versant-ventures/)

---
JSON: https://onco.cc/api/v1/entities/nested-therapeutics.json